440 related articles for article (PubMed ID: 36167468)
21. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Majzner RG; Ramakrishna S; Yeom KW; Patel S; Chinnasamy H; Schultz LM; Richards RM; Jiang L; Barsan V; Mancusi R; Geraghty AC; Good Z; Mochizuki AY; Gillespie SM; Toland AMS; Mahdi J; Reschke A; Nie EH; Chau IJ; Rotiroti MC; Mount CW; Baggott C; Mavroukakis S; Egeler E; Moon J; Erickson C; Green S; Kunicki M; Fujimoto M; Ehlinger Z; Reynolds W; Kurra S; Warren KE; Prabhu S; Vogel H; Rasmussen L; Cornell TT; Partap S; Fisher PG; Campen CJ; Filbin MG; Grant G; Sahaf B; Davis KL; Feldman SA; Mackall CL; Monje M
Nature; 2022 Mar; 603(7903):934-941. PubMed ID: 35130560
[TBL] [Abstract][Full Text] [Related]
22. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Gargett T; Truong NTH; Gardam B; Yu W; Ebert LM; Johnson A; Yeo ECF; Wittwer NL; Tapia Rico G; Logan J; Sivaloganathan P; Collis M; Ruszkiewicz A; Brown MP
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754916
[TBL] [Abstract][Full Text] [Related]
23. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
[TBL] [Abstract][Full Text] [Related]
25. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
26. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model.
Murty S; Haile ST; Beinat C; Aalipour A; Alam IS; Murty T; Shaffer TM; Patel CB; Graves EE; Mackall CL; Gambhir SS
Oncoimmunology; 2020 May; 9(1):1757360. PubMed ID: 32923113
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
Front Immunol; 2020; 11():594271. PubMed ID: 33224149
[TBL] [Abstract][Full Text] [Related]
28. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
29. Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives.
Karschnia P; Teske N; Thon N; Subklewe M; Tonn JC; Dietrich J; von Baumgarten L
Neurology; 2021 Aug; 97(5):218-230. PubMed ID: 33986138
[TBL] [Abstract][Full Text] [Related]
30. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo.
Li X; Zhao L; Li W; Gao P; Zhang N
Genes Immun; 2024 Jun; 25(3):201-208. PubMed ID: 38702509
[TBL] [Abstract][Full Text] [Related]
31. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
[TBL] [Abstract][Full Text] [Related]
32. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
34. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
Feldman L; Brown C; Badie B
Neuromolecular Med; 2022 Mar; 24(1):35-40. PubMed ID: 34665390
[TBL] [Abstract][Full Text] [Related]
36. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
Seitz CM; Schroeder S; Knopf P; Krahl AC; Hau J; Schleicher S; Martella M; Quintanilla-Martinez L; Kneilling M; Pichler B; Lang P; Atar D; Schilbach K; Handgretinger R; Schlegel P
Oncoimmunology; 2020; 9(1):1683345. PubMed ID: 32002293
[TBL] [Abstract][Full Text] [Related]
37. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
38. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract][Full Text] [Related]
39. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
40. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
Gargett T; Brown MP
Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
